Novel therapeutics and emerging technology in haemostasis and thrombosis: highlights from the British society for haemostasis and thrombosis annual meeting

The 2023 annual meeting of the British Society for Haemostasis and Thrombosis (BSHT) was held in Birmingham, United Kingdom. The theme of this year's meeting was novel therapeutics and emerging technology. Here, the exciting research presented at the meeting is discussed

Platelet–Neutrophil Interaction and Thromboinflammation in Diabetes: Considerations for Novel Therapeutic Approaches

Thromboinflammation has become a topic of key interest in cardiovascular disease and the prevention of diabetes complications because of the interplay between thrombosis and inflammation in diabetes. Specifically, the significant risk of vascular thrombotic disease in diabetes highlights the need for new and better therapeutic targets to help manage and prevent vascular thrombo‐occlusive disease in this condition. Similarly, the prominent role of inflammation in diabetes has sparked interest in anti‐inflammatory agents to better prevent and control vascular disease. Investigations on the effects of anticoagulation and antiplatelet interventions in patients with diabetes and cardiovascular disease show a potential role for these agents in decreasing morbidity and mortality. Neutrophils and platelets are key players in inflammation and wound‐healing response, respectively. The interaction between neutrophils and platelets is thought to be an important driver of thromboinflammation. Therefore, this review describes the mechanisms involved in platelet–neutrophil interactions that contribute to the development or exacerbation of thromboinflammation in the context of diabetes and its associated comorbidities. The effects observed by the antithrombotic/antidiabetic treatments and physical activity/dietary interventions on attenuating thromboinflammation are discussed. These data suggest that mechanisms involved in platelet–neutrophil interaction, platelet activation/aggregation, and the recruitment of neutrophils have a promising potential to become therapeutic targets to decrease thromboinflammation in patients with diabetes

Novel therapeutics and emerging technology in haemostasis and thrombosis: highlights from the British Society for Haemostasis and thrombosis annual meeting.

The BSHT held its annual meeting between January 25th and 27th 2023 at the Edgbaston Park Hotel & Conference Centre, Birmingham, United Kingdom. The meeting is an opportunity for academic researchers, biomedical scientists and clinicians to network and learn about recent advancements in the field of haemostasis and thrombosis. The meeting was attended by 144 delegates from 9 countries and included a selection of clinical, translational and basic science communications. Additional content included an Early Career Researcher (ECR) networking event and plenary speakers, industry-supported symposia, Scientist in Training, Emerging Fellows and Clinical Education sessions. Recipients of BSHT Summer Studentships also presented their projects as short oral presentations. There were also 14 excellent posters with a good range of topic areas, from basic science studies to novel reagent development and pre-clinical trial data